Table 1 Characteristics of study population and comparison with main study population
Patients in PET-study (N = 151) | Remaining study population without COPD (N = 819) | P-value | |
|---|---|---|---|
Age (IQR) – yr. | 62 (55–69) | 63 (55–71) | 0.33 |
Male sex – no. (%) | 104 (69) | 608 (74) | 0.17 |
Body-mass index (IQR) – kg/m2 | 26.6 (24.1–29.8) | 26.9 (23.9–30.2) | 0.71 |
NT-pro-BNP (IQR) – pg/ml | 851 (466–1848) | 1220 (618–2274) | < 0.01 |
eGFR (IQR) – ml/min/ 1.73 m2 | 78 (63–94) | 73 (58–92) | 0.03 |
Left ventricular ejection fraction (IQR) – % | 25 (20–31) | 25 (20–30) | 0.04 |
Coexisting conditions – no. (%) | |||
Diabetes mellitus – no. (%) | 19 (13) | 160 (20) | 0.04 |
Hypertension | 47 (31) | 257 (31) | 0.94 |
Left bundle branch block – no. (%) | 83 (60) | 480 (65) | 0.22 |
Cause of heart failure – no. (%) | |||
Idiopathic | 118 (78) | 615 (75) | 0.32 |
Valvular | 9 (6) | 31 (4) | |
Hypertension | 11 (7) | 88 (11) | |
Other | 13 (9) | 85 (10) | |
Medications – no. (%) | |||
ACE-inhibitor or ARB | 149 (99) | 785 (96) | 0.09 |
Beta blocker | 145 (96) | 747 (91) | 0.05 |
Aldosterone receptor antagonist | 86 (57) | 471 (58) | 0.90 |
Statins | 60 (40) | 356 (43) | 0.39 |
Anticoagulation treatment | 54 (36) | 314 (38) | 0.55 |
Acetylsalicylic acid | 53 (35) | 308 (38) | 0.56 |
Device therapy – no. (%) | |||
CRT | 75 (50) | 496 (61) | 0.01 |